Multiple organisms have been isolated from infected sinuses. However, it is important to note that "normal flora" has been cultured from healthy uninfected sinuses. "Normal flora" include ...

People who suffer from chronic sinus infections know the warning signs when one might be coming on. Doctors at Baylor College of Medicine say that is a good time to try preventative measures, such as ...

For millions of Americans, paying for the treatment needed to manage their diseases can become its own lifelong problem.

Six months after Amgen and AstraZeneca reported promising results for Tezspire (tezepelumab) as a potential treatment for ...

Let’s take a look at what the three best months are in 2025! If you love summer, you will love it even more this year because these should be some of our best and most positive months starting ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps ...

Jessica is a writer on the Wellness team with a focus on health technology, eye care, nutrition and finding new approaches to chronic health problems. When she's not reporting on health facts ...

All ratings are determined solely by our editorial team. Fidelity’s three-month CD scores so well because it offers a robust 4.50% APY. Your CD also comes with the standard $250,000 in FDIC ...

CRSwNP is a chronic condition that affects up to 4% of ... Depemokimab is an ultra-long-acting biologic administered once every six months. Price Action: GSK stock is up 0.80% at $39.14 during ...

It indicates an expandable section or menu, or sometimes previous / next navigation options. Affiliate links for the products on this page are from partners that compensate us and terms apply to ...

Inspire is increasing its full year 2024 revenue guidance to between $793 million to $798 million, which represents growth of 27% to 28% over full year 2023 revenue of $624.8 million. This compares to ...